Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery

Marie Stark, R. Holland Cheng

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery. Nanotheranostic molecules can be packaged in the hollow nanocapsid shell during in vitro assembly. Complementing the adapted stability and cell-entry characteristics of the HEV capsid, a modified nanocapsid serves as a tunable tumor-targeting platform for nanotheronostic delivery.

Original languageEnglish (US)
Pages (from-to)307-317
Number of pages11
JournalPharmaceutical patent analyst
Volume5
Issue number5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Hepatitis E virus
Capsid
Neoplasms
Nanoparticles
Biological Availability
Therapeutics

Keywords

  • cancer targeting
  • nanotheranostics
  • viral capsid

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery. / Stark, Marie; Cheng, R. Holland.

In: Pharmaceutical patent analyst, Vol. 5, No. 5, 01.09.2016, p. 307-317.

Research output: Contribution to journalReview article

@article{4cbbbb6817b24b2fa241ed7556e7e8fc,
title = "Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery",
abstract = "Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery. Nanotheranostic molecules can be packaged in the hollow nanocapsid shell during in vitro assembly. Complementing the adapted stability and cell-entry characteristics of the HEV capsid, a modified nanocapsid serves as a tunable tumor-targeting platform for nanotheronostic delivery.",
keywords = "cancer targeting, nanotheranostics, viral capsid",
author = "Marie Stark and Cheng, {R. Holland}",
year = "2016",
month = "9",
day = "1",
doi = "10.4155/ppa-2016-0021",
language = "English (US)",
volume = "5",
pages = "307--317",
journal = "Pharmaceutical patent analyst",
issn = "2046-8954",
publisher = "Future Science",
number = "5",

}

TY - JOUR

T1 - Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery

AU - Stark, Marie

AU - Cheng, R. Holland

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery. Nanotheranostic molecules can be packaged in the hollow nanocapsid shell during in vitro assembly. Complementing the adapted stability and cell-entry characteristics of the HEV capsid, a modified nanocapsid serves as a tunable tumor-targeting platform for nanotheronostic delivery.

AB - Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery. Nanotheranostic molecules can be packaged in the hollow nanocapsid shell during in vitro assembly. Complementing the adapted stability and cell-entry characteristics of the HEV capsid, a modified nanocapsid serves as a tunable tumor-targeting platform for nanotheronostic delivery.

KW - cancer targeting

KW - nanotheranostics

KW - viral capsid

UR - http://www.scopus.com/inward/record.url?scp=85015351094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015351094&partnerID=8YFLogxK

U2 - 10.4155/ppa-2016-0021

DO - 10.4155/ppa-2016-0021

M3 - Review article

VL - 5

SP - 307

EP - 317

JO - Pharmaceutical patent analyst

JF - Pharmaceutical patent analyst

SN - 2046-8954

IS - 5

ER -